. The phenotype of angiotensin converting enzyme (ACE) knockout mice is a complex combination of cardiovascular, reproductive, hematologic and renal defects. This diversity of abnormalities supports the idea that ACE and angiotensin II influence many physiologic processes beyond simple blood pressure control. ACE is a zinc metalloproteinase composed of two regions termed N- and C-terminal domains. These domains are highly homologous but have somewhat different properties. In particular, while both domains can cleave angiotensin I, the tetrapeptide AcSDKP is exclusively cleaved by the N- domain. To investigate the in vivo roles of each domain, I created two new strains of mice. These mice were generated by homologous recombination in order to mutate the specific amino acids responsible for zinc binding (and thus catalysis) in each domain. In mice termed N-KO, the N-terminal domain of ACE is inactivated. In C-KO mice, it is the C-terminal domain that is no longer catalytic. The cardiovascular and renal phenotypes of N-KO and C-KO mice are indistinguishable from this of wild-type. These mouse models are ideal to study specific functions of ACE independent of blood pressure changes, a typical bias in studying the RAS with pharmacologic manipulations.
My first aim i s to complete the characterization of the C-KO mice. This investigation will be performed during the mentored phase of this grant. The next aims will be fully developed during the independent phase.
The second aim i s to investigate the in vivo function of the two catalytic sites of ACE in the progression of pulmonary fibrosis using bleomycin-induced lung injury as a model. My hypothesis is that ACE controls the concentration of both pro-fibrotic (angiotensin II) and anti-fibrotic (AcSDKP) molecules. My preliminary data strongly suggest that the N-KO mice are protected against bleomycin-induced lung injury. I find this in studies using both low and high doses of bleomycin.
The third aim i s to identify the mechanism responsible of this resistance. My hypothesis is that AcSDKP, elevated in N-KO mice, inhibits the progression of lung fibrosis. Relevance. This proposal will yield fundamental knowledge about the importance of ACE and its multiple substrates in tissue injury. Finally, my studies are both interesting and relevant to a variety of human diseases, including diseases of the lung, heart and kidney.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Career Transition Award (K99)
Project #
5K99HL088000-02
Application #
7323287
Study Section
Special Emphasis Panel (ZHL1-CSR-M (F1))
Program Officer
Colombini-Hatch, Sandra
Project Start
2006-12-01
Project End
2008-03-04
Budget Start
2007-12-01
Budget End
2008-03-04
Support Year
2
Fiscal Year
2008
Total Cost
$21,583
Indirect Cost
Name
Emory University
Department
Pathology
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Gonzalez-Villalobos, Romer A; Janjoulia, Tea; Fletcher, Nicholas K et al. (2013) The absence of intrarenal ACE protects against hypertension. J Clin Invest 123:2011-23
Ong, Frank S; Lin, Chentao X; Campbell, Duncan J et al. (2012) Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity. Hypertension 59:283-90
Bernstein, Kenneth E; Shen, Xiao Z; Gonzalez-Villalobos, Romer A et al. (2011) Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 11:105-11
Li, Ping; Xiao, Hong D; Xu, Jianguo et al. (2010) Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. Am J Pathol 177:1113-21
Weiss, Daiana; Bernstein, Kenneth E; Fuchs, Sebastian et al. (2010) Vascular wall ACE is not required for atherogenesis in ApoE(-/-) mice. Atherosclerosis 209:352-8
Campbell, Duncan J; Xiao, Hong D; Fuchs, Sebastien et al. (2009) Genetic models provide unique insight into angiotensin and bradykinin peptides in the extravascular compartment of the heart in vivo. Clin Exp Pharmacol Physiol 36:547-53
Fuchs, Sebastien; Xiao, Hong D; Hubert, Christine et al. (2008) Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51:267-74
Xiao, Hong D; Fuchs, Sebastien; Bernstein, Ellen A et al. (2008) Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy. Am J Physiol Heart Circ Physiol 294:H659-67
Shen, Xiao Z; Xiao, Hong D; Li, Ping et al. (2008) New insights into the role of angiotensin-converting enzyme obtained from the analysis of genetically modified mice. J Mol Med 86:679-84